Recent News

• 06.05.2025 - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 06.05.2025 - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 05.29.2025 - Mitchell Kapoor
• 05.21.2025 - RBC Capital Markets Global Healthcare Conference
• 05.18.2025 - Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
• 05.18.2025 - Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
• 05.13.2025 - Bank of America Securities Health Care Conference
• 05.08.2025 - Intellia Therapeutics First Quarter 2025 Earnings Conference Call
• 05.08.2025 - Intellia Therapeutics First Quarter 2025 Earnings Conference Call
• 05.08.2025 - Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Recent Filings

• 05.28.2025 - 8-K Current report
• 05.19.2025 - 8-K Current report
• 05.19.2025 - EX-99.1 EX-99.1
• 05.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 8-K Current report